Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c

Table 3 Mean hemoglobin A1c before and after hepatitis C virus treatment by hepatitis C virus genotype and sustained virologic response 12-wk status

Genotype	Before DAA	SE	After DAA	SE	P-value
Mean HbA1c of patients who did achieve SVR12
1a	7.5	0.19	6.68	0.14	0.001
1b	7.3	0.22	6.59	0.21	0.03
2	7.09	0.35	6.29	0.21	0.06
3	7.12	0.37	6.10	0.39	0.08
4	5.5	NA	5.30	NA	NA
Overall	7.35	0.13	6.55	0.11	< 0.01
Mean HbA1c of patients who did not achieve SVR12
1a	8.98	1.14	8.95	1.41	0.98
1b	6.4	NA	6.50	NA	NA
2	No observations
3	8.5	NA	8.70	NA	NA
4	No observations
Overall	8.6	0.89	8.61	1.08	0.99

HbA1c: Hemoglobin A1c; SVR12: Sustained virologic response 12 wk after treatment; DAA: Direct acting antiviral; SE: Standard error.